Although mild CTRCD was common, prospective studies are required to determine the clinical relevance of changes in GLS in patients treated with BRAF and MEK inhibitors.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: In patients with melanoma treated with BRAF and MEK inhibitors, the development of CTRCD is common. The gene discussed is BRAF; the disease is melanoma.